ANGIODYNAMICS INC Stock Forecasts | ANGO EPS & Price Predictions

11 | 30 | 2022 ANGIODYNAMICS Piper Sandler Healthcare Conference Jim Clemmer, President & CEO Stephen Trowbridge, Executive VP & CFO 1

2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “projects,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2022. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason. In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition. Notice Regarding Non-GAAP Financial Measures Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics’ business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported adjusted EBITDA (income before interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics’ performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics’ underlying business. Management encourages investors to review AngioDynamics’ financial results prepared in accordance with GAAP to understand AngioDynamics’ performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics’ financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

3 AngioDynamics Strategic Plan FOCUSED TRANSFORMATION PURSUING LARGER MARKETS U.S. Total Addressable Markets FY2021 - $3.0B Launch of the Auryon System gives us access to the peripheral atherectomy market FY2023 - $6.0B Planned Thrombectomy & NanoKnife System portfolio additions & new indications increase market access FY2025 - $8.0B Planned Thrombectomy & PE portfolio additions & new indications increase market access Progress toward transforming Angiodynamics into a technology focused growth company FY2018 - $1.3B Began our strategic initiative to become a growth company FOCUS ON LARGER, FASTER GROWING ADDRESSABLE MARKETS Relying on Angiodynamics technology & innovation to produce measurable patient outcomes RESOURCE ALLOCATION Focused on functional areas that create our competitive advantages PORTFOLIO TRANSFORMATION Transformation & strength is driven by R&D, M&A, and Clinical & Regulatory EMBRACE DIFFERENTIATION Exploit Angiodynamics unique value propositions via internal talent and technology CREATE VALUE Drive value creation through portfolio management and expansion of indications Thrombus Management Peripheral Arterial Disease Solid Tumor Vascular Access Catheters & Accessories Microwave & Radiofrequency Ablation Diagnostic Catheters, Guidewires & Kits Lung Biopsy Safety Endovenous Laser Treatment Radiation Treatment Stabilization Balloons Invest for GROWTH in Med Tech MAINTAIN Positioning in Med Device The planned portfolio additions and new indications are based on management estimates and industry sources as of July 2022 and are not guarantees of future performance and are subject to risks and uncertainties including FDA clearance. Investors are cautioned that actual events or results may differ from AngioDynamics’ expectations.

THROMBUS MANAGEMENT MED TECH

5 Thrombus Management Source: Management estimate & industry sources as of July 2022. *Includes Clot in Transit The AngioVac System allows for the continuous aspiration of embolic material such as fresh, soft thrombi or vegetation from the venous system while Simultaneously reinfusing the patient’s own filtered blood to limit procedural blood loss MULTIPLE TIP ANGLES 00, 200, 850, 1800 Proprietary Funnel Design Allows for Massive Clot Removal | En Bloc Radiopaque Markers Better Tip Visibility Large End Hole Aspiration 42FR & 30FR Opening The AlphaVac System allows for the controlled aspiration of embolic material such as fresh, soft thrombi or vegetation from the venous system MULTIPURPOSE MECHANICAL ASPIRATION DVT Pulmonary Embolism PE A blood clot that forms in a deep vein, usually the leg, groin or arm A DVT breaks free and travels to the lungs blocking some or all of the blood supply + = Venous Thromboembolism VTE Deep Vein Thrombosis DVT and PE are collectively referred to as VTE $80M $2.1B $1.8B PULMONARY EMBOLISM* RIGHT ATRIUM DEEP VEIN THROMBOSIS 2022 TAM M A R K E T O P P O R T U N I T Y C U R R E N T P R O D U C T S Purpose built portfolio developed in partnership with physicians

PERIPHERAL ATHERECTOMY MED TECH

7 Peripheral Atherectomy 2.35 mm Aspiration and Off-Center capabilities and indicated for Peripheral Atherectomy and In-Stent Restenosis (ISR) 2.0 mm Aspiration capability and indicated for Peripheral Atherectomy and ISR 1.5 mm Indicated for Peripheral Atherectomy 0.9 mm Indicated for Peripheral Atherectomy $760M Source: Peripheral Vascular Devices Medtech 360 Market Analysis US December, 2021. Millennium Research Group, Inc. 7 2022 Served Market Above the Knee (ATK) Below the Knee (BTK) Office Based Lab (OBL) Hospital Why wavelength matters Each type of tissue interacts differently with a given wavelength The Auryon System produces a photon energy of 3.5eV, which is low enough to be nonreactive to vessel endothelium, but high enough to vaporize calcium.1,2 Why pulse width and amplitude matter Greater amplitude is achieved with shorter pulses, which can deposit energy before thermal diffusion occurs. The Auryon System has a pulse width of 10 to 25ns, ensuring enough power to target the lesion and spare the vessel.3 1. Herzog A, Bogdan S, Glikson M, Ishaaya AA, Love C. Selective tissue ablation using laser radiation at 355 nm in lead extraction by a hybrid catheter; a preliminary report. Lasers Surg Med. 2016;48(3):281-287. 2. Spectranetics Corporation. CVX-300 Excimer Laser System: Operator’s Manual. Version 28. 2019:1-56. 3. Auryon. Instructions for use. AngioDynamics; 2019.

IRREVERSIBLE ELECTROPORATION MED TECH 8

9 Irreversible Electroporation (IRE) How does IRE work? Using short electric pulses between probes, NanoKnife destroys cells without relying on extreme heat or cold Why this is different? This patented technology facilitates functional tissue regeneration post ablation and spares vital structures within the ablation zone Approximately 100,000 men are estimated to be candidates for focal therapy each year8 Effectively destroys targeted tissue with precise treatment margins5 Spares vital structures within the ablation zone6 Enables treatment to be performed in all segments of an organ7 Bridge the gap between an active surveillance strategy and whole-gland treatment Prostate cancer (PCa) is the only solid tumor without a standardized local treatment option1 Advances in genetics, imaging, and methodology support a local treatment option for PCa2 But existing technology has less than ideal outcomes for cancer control and quality of life3,4 1). NCCN Guidelines for Patients Early Stage Prostate Cancer. https://www.nccn.org/patients/guidelines/content/PDF/prostate-early-patient.pdf. 2). Lee, Byron H., et al. “Changing Landscape of Prostate Cancer Favoring Low-Risk Prostate Cancer: Implications for Active Surveillance Versus Focal Therapy.” Imaging and Focal Therapy of Early Prostate Cancer, 2012, pp. 17–36., doi:10.1007/978-1-62703-182-0_2. 3). Worrell Design. Next Gen Voice of Customer, 2020. 4). Sivaraman A, Barret E. Focal Therapy for Prostate Cancer: An "À la Carte" Approach. Eur Urol. 2016;69(6):973-975. doi:10.1016/j.eururo.2015.12.015 5). Lee EW, Thai S, Kee ST. Irreversible electroporation: a novel image-guided cancer therapy. Gut Liver. (2010);4(SUPPL. 1):99–104. doi: 10.5009/gnl.2010.4.S1.S99 6). Li W, Fan Q, Ji Z, Qiu X, Li Z. The effects of irreversible electroporation (IRE) on nerves. PLoS One. 2011 Apr 14;6(4):e18831. doi: 10.1371/journal.pone.0018831. PMID: 21533143; PMCID: PMC3077412. 7). Scheltema MJ, Chang JI, van den Bos W, Gielchinsky I, Nguyen TV, Reijke TM, Siriwardana AR, Böhm M, de la Rosette JJ, Stricker PD. Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments. Diagn Interv Radiol. 2018 Sep;24(5):268-275. doi: 10.5152/dir.2018.17374. PMID: 30211680; PMCID: PMC6135060. 8). Cancer Facts & Figures 2021. American Cancer Society. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html. Accessed January 4, 2022. PRESERVE IDE – Prostate Initiative

10 AngioDynamics: A Technology Focused Strategy MANAGEMENT NOTE: FOCUS ON LARGER, FASTER GROWING ADDRESSABLE MARKETS Differentiated platforms and pursuit of clinical data generation enables access into larger, growing addressable markets. INVEST IN MED TECH SEGMENT Investment in Med Tech growth driven by execution in Med Device. CREATE VALUE Strategic portfolio management combined with R&D, M&A, and Clinical & Regulatory pathway expansion to drive value creation. Management expects cash at the end of the second fiscal quarter, ended November 30, 2022, to be approximately $28 – $30 million; an increase in net cash from the end of the first fiscal quarter of approximately $3.5 – $5.5 million. This expectation does not include the $4.2 million receivable related to the CARES Act. The Company expects to report results for its second fiscal quarter ended November 30, 2022, on or around January 5, 2023, in accordance with its typical schedule.

11 | 30 | 2022 ANGIODYNAMICS Piper Sandler Healthcare Conference Jim Clemmer, President & CEO Stephen Trowbridge, Executive VP & CFO 11